| Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study P Fenaux, GJ Mufti, E Hellstrom-Lindberg, V Santini, C Finelli, ... The lancet oncology 10 (3), 223-232, 2009 | 2982 | 2009 |
| Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia BD Cheson, PL Greenberg, JM Bennett, B Lowenberg, PW Wijermans, ... Blood 108 (2), 419-425, 2006 | 1801 | 2006 |
| Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia P Fenaux, GJ Mufti, E Hellström-Lindberg, V Santini, N Gattermann, ... Journal of clinical oncology 28 (4), 562-569, 2010 | 1162 | 2010 |
| Report of an international working group to standardize response criteria for myelodysplastic syndromes BD Cheson, JM Bennett, H Kantarjian, A Pinto, CA Schiffer, SD Nimer, ... Blood, The Journal of the American Society of Hematology 96 (12), 3671-3674, 2000 | 915 | 2000 |
| Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms SD Gore, S Baylin, E Sugar, H Carraway, CB Miller, M Carducci, M Grever, ... Cancer research 66 (12), 6361-6369, 2006 | 597 | 2006 |
| Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure T Prébet, SD Gore, B Esterni, C Gardin, R Itzykson, S Thepot, F Dreyfus, ... Journal of Clinical Oncology 29 (24), 3322, 2011 | 518 | 2011 |
| Elevated expression of the apoptotic regulator Mcl-1 at the time of leukemic relapse SH Kaufmann, JE Karp, PA Svingen, S Krajewski, PJ Burke, SD Gore, ... Blood, The Journal of the American Society of Hematology 91 (3), 991-1000, 1998 | 438 | 1998 |
| Acute myeloid leukemia, version 3.2017, NCCN clinical practice guidelines in oncology MR O'Donnell, MS Tallman, CN Abboud, JK Altman, FR Appelbaum, ... Journal of the National Comprehensive Cancer Network 15 (7), 926-957, 2017 | 420 | 2017 |
| MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation ME Figueroa, L Skrabanek, Y Li, A Jiemjit, TE Fandy, E Paietta, ... Blood, The Journal of the American Society of Hematology 114 (16), 3448-3458, 2009 | 399 | 2009 |
| Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias I Gojo, A Jiemjit, JB Trepel, A Sparreboom, WD Figg, S Rollins, ML Tidwell, ... Blood 109 (7), 2781-2790, 2007 | 364 | 2007 |
| Arsenic trioxide—an old drug rediscovered A Emadi, SD Gore Blood reviews 24 (4-5), 191-199, 2010 | 331 | 2010 |
| Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies TE Fandy, JG Herman, P Kerns, A Jiemjit, EA Sugar, SH Choi, AS Yang, ... Blood, The Journal of the American Society of Hematology 114 (13), 2764-2773, 2009 | 306 | 2009 |
| Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia G Garcia-Manero, SD Gore, C Cogle, R Ward, T Shi, KJ MacBeth, E Laille, ... Journal of Clinical Oncology 29 (18), 2521, 2011 | 279 | 2011 |
| Myelodysplastic syndromes PL Greenberg, E Attar, JM Bennett, CD Bloomfield, CM De Castro, ... Journal of the National Comprehensive Cancer Network 9 (1), 30-56, 2011 | 260 | 2011 |
| Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the … T Prebet, Z Sun, ME Figueroa, R Ketterling, A Melnick, PL Greenberg, ... Journal of Clinical Oncology 32 (12), 1242-1248, 2014 | 248 | 2014 |
| DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes EA Griffiths, SD Gore Seminars in hematology 45 (1), 23-30, 2008 | 243 | 2008 |
| Randomized phase II study of azacitidine alone or in combination with lenalidomide or with vorinostat in higher-risk myelodysplastic syndromes and chronic myelomonocytic … MA Sekeres, M Othus, AF List, O Odenike, RM Stone, SD Gore, MR Litzow, ... Journal of Clinical Oncology 35 (24), 2745, 2017 | 236 | 2017 |
| Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher‐risk myelodysplastic syndromes LR Silverman, P Fenaux, GJ Mufti, V Santini, E Hellström‐Lindberg, ... Cancer 117 (12), 2697-2702, 2011 | 229 | 2011 |
| Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia SD Gore, LJ Weng, WD Figg, S Zhai, RC Donehower, G Dover, ... Clinical Cancer Research 8 (4), 963-970, 2002 | 219 | 2002 |
| Autoimmune phenomena in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia MW Saif, JL Hopkins, SD Gore Leukemia & lymphoma 43 (11), 2083-2092, 2002 | 210 | 2002 |
